Population Pharmacokinetics of High-Dose Continuous-Infusion Meropenem and Considerations for Use in the Treatment of Infections Due to KPC-Producing Klebsiella pneumoniae

We assessed the population pharmacokinetics of high-dose continuous-infusion (HDCI) meropenem in a cohort of patients with Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae (KPC-Kp) infections. Monte Carlo simulations were used to define the permissible HDCI meropenem regimen...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Antimicrob Agents Chemother
Egile Nagusiak: Cojutti, Piergiorgio, Sartor, Assunta, Righi, Elda, Scarparo, Claudio, Bassetti, Matteo, Pea, Federico
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society for Microbiology 2017
Gaiak:
Clinical Therapeutics
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5610526/
https://ncbi.nlm.nih.gov/pubmed/28760900
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00794-17
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak